Cargando…

Using Negative Control Outcomes and Difference-in-Differences Analysis to Estimate Treatment Effects in an Entirely Treated Cohort: The Effect of Ivacaftor in Cystic Fibrosis

When an entire cohort of patients receives a treatment, it is difficult to estimate the treatment effect in the treated because there are no directly comparable untreated patients. Attempts can be made to find a suitable control group (e.g., historical controls), but underlying differences between t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Newsome, Simon J, Daniel, Rhian M, Carr, Siobhán B, Bilton, Diana, Keogh, Ruth H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Practice of Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914944/ https://www.ncbi.nlm.nih.gov/pubmed/34753177 http://dx.doi.org/10.1093/aje/kwab263

Ejemplares similares

Mediation of the total effect of cystic fibrosis‐related diabetes on mortality: A UK Cystic Fibrosis Registry cohort study
por: Tanner, Kamaryn T., et al.
Publicado: (2022)

Data Resource Profile: The UK Cystic Fibrosis Registry
por: Taylor-Robinson, David, et al.
Publicado: (2018)

Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?
por: Granger, Emily, et al.
Publicado: (2022)

Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience
por: Higgins, Mark, et al.
Publicado: (2020)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

How Clinically Efficient Is Lumacaftor/Ivacaftor for Cystic Fibrosis Patients? An Updated Literature Review
por: Perveen, Sumera, et al.
Publicado: (2020)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification
por: Lunt, Mark, et al.
Publicado: (2009)

Analysis of Longitudinal Studies With Repeated Outcome Measures: Adjusting for Time-Dependent Confounding Using Conventional Methods
por: Keogh, Ruth H, et al.
Publicado: (2018)

Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022)

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
por: O’Reilly, Ruth, et al.
Publicado: (2013)

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018)

Effect of Ivacaftor on Objective and Subjective Measures of Cough in Patients with Cystic Fibrosis
por: Faruqi, Shoaib, et al.
Publicado: (2016)

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion
por: Colombo, C., et al.
Publicado: (2021)

Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis
por: Vadagam, Pratyusha, et al.
Publicado: (2018)

Estimating long‐term treatment effects in observational data: A comparison of the performance of different methods under real‐world uncertainty
por: Newsome, Simon J., et al.
Publicado: (2018)

The changing demography of the cystic fibrosis population: forecasting future numbers of adults in the UK
por: Keogh, Ruth H., et al.
Publicado: (2020)

Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor
por: Petrocheilou, Argyri, et al.
Publicado: (2020)

Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome
por: Marsh, Ryan, et al.
Publicado: (2023)

The effect of elexacaftor/tezacaftor/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis
por: Allgood, Sarah, et al.
Publicado: (2023)

Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
por: Piehler, Linus, et al.
Publicado: (2023)

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
por: Pilewski, Joseph M., et al.
Publicado: (2020)

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
por: Schwarz, Carsten, et al.
Publicado: (2021)

Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data()
por: Keogh, Ruth H., et al.
Publicado: (2018)

Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis–Related Diabetes
por: Christian, Francis, et al.
Publicado: (2019)

Combination Therapy with Lumacaftor–Ivacaftor in Cystic Fibrosis. Keeping It Real
por: Sala, Marc A., et al.
Publicado: (2020)

Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis
por: Mésinèle, Julie, et al.
Publicado: (2022)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022)

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial
por: Nichols, David P., et al.
Publicado: (2021)

Health State Utility Data in Cystic Fibrosis: A Systematic Review
por: Mohindru, Bishal, et al.
Publicado: (2019)

Dynamic Prediction of Survival in Cystic Fibrosis: A Landmarking Analysis Using UK Patient Registry Data
por: Keogh, Ruth H., et al.
Publicado: (2019)

Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
por: Connett, GJ
Publicado: (2019)

Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis
por: Shiferaw, Dejene, et al.
Publicado: (2019)

Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations
por: Csanády, László, et al.
Publicado: (2019)

ICER releases evidence report on elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2020)

Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis
por: Hisert, Katherine B., et al.
Publicado: (2020)

Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients
por: Neerincx, Anne H., et al.
Publicado: (2021)

Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator
por: Laselva, Onofrio, et al.
Publicado: (2021)

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
por: Hanafin, Patrick O., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_subfgv7iir647r16sq5dp6vklm